In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CryoCath Technologies

This article was originally published in The Gray Sheet

Executive Summary

Canadian initial public offering raises approximately $25.9 mil. (based on current exchange rates) to support clinical trials and commercialization of the Freezor focal ablation catheter system for tachyarrhythmia treatment, including atrial fibrillation. The funds also will go toward trials of the firm's CryoStent for post-angioplasty restenosis and CryoVasc system for cardiac ischemia. The offering included 5 mil. shares at about $5.17 each. The stock is listed on the Toronto exchange under the symbol "CYT." The IPO syndicate was led by Yorkton Securities and included CIBC World Markets, National Bank Financial and Loewen, Ondaatje, McCutcheon Limited



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts